Stimlabs, LLC

Stimlabs, LLC specializes in animal-derived wound matrix dressings, which are designed to aid in wound care. These products, such as Corplex P, Theracor, and Allacor P, are intended to support tissue regeneration and promote healing in chronic or acute wounds. The focus is on regenerative wound management rather than invasive or electronic devices.

Stimlabs, LLC is based in the United States, meaning its devices fall under FDA jurisdiction. Since these products are classified as Class II (U) devices, they are subject to FDA’s 510(k) premarket notification process and must comply with UDI (Unique Device Identification) requirements. The U.S. location also influences compliance with domestic regulatory standards, though individual devices—not the company—are evaluated for authorization.

Stimlabs, LLC’s devices are listed in the FDA’s 510(k) and UDI registries because these are the primary U.S. systems for tracking Class II medical devices. The 510(k) registry documents premarket submissions proving substantial equivalence to predicate devices, while the UDI system ensures traceability and transparency in the supply chain. Both registries are mandatory for FDA-authorized devices in these categories.

Stimlabs, LLC’s animal-derived wound matrix dressings are classified as FDA Class II (U) devices. This classification is based on their intended use—supporting tissue regeneration in wounds—rather than posing significant risk. Class II devices require special controls (e.g., performance standards, labeling requirements) to ensure safety and effectiveness, but they do not require clinical trials like higher-risk Class III devices. The ‘U’ designation indicates they are unclassified under specific FDA categories but still subject to regulatory oversight.